Tilogotamab (Synonyms: HexaBody-DR5/DR5; Hx-DR5-01/05)

Cat. No.: HY-P99559 Purity: 99.31%: FAQs
Data Sheet
SDS

COA
Technical Support

Tilogotamab is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM).

For research use only. We do not sell to patients.

CAS No. : 2109731-10-2

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Tilogotamab Featured Recommendations:

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vivo

Tilogotamab (20 μg/mL; 24 h) induces potent cytotoxicity of primary MM cells^[1].
Tilogotamab is a mixture of 2 noncompeting DR5-specific immunoglobulin G1 (IgG1) antibodies, each with an E430G mutation in the Fc domain. This mutation enhances Fc-Fc interactions, resulting in antibody hexamerization, followed by FcγR-independent clustering of DR5 molecules^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

144880.00

CAS No.

2109731-10-2

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Tilogotamab]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format

Human IgG1 kappa

Biological Activity

Immobilized Human TNFRSF10B/TRAILR2/CD262, Fc Tag can bind Tilogotamab. The EC₅₀ for this effect is 158.9 ng/mL.

Purity & Documentation

Purity: 99.31%

Select Batch:

Data Sheet (255 KB) SDS (251 KB)

COA (231 KB) SDS-PAGE (83 KB) SEC-HPLC (225 KB)

Inhibitory Antibodies User Guide (602 KB)

References

[1]. Horst HJ, et, al. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2165-2172. [Content Brief]

Tilogotamab Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tilogotamab2109731-10-2HexaBody-DR5/DR5 Hx-DR5-01/05OthersDR5death receptor type 5multiple myelomaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #